YGYing Gao

Ying Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ying Gao has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plasma D‐Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor‐Node‐Metastasis Classification (TNM), and Treatment of Non‐Small‐Cell Lung Cancer (NSCLC) Patients

    by Jiqiang Guo, Ying Gao, Zhihua Gong, Pengfei Dong, Yajie Mao, Fang Li, Jianrong Rong, Junping Zhang, Yongnian Zhou, Huijing Feng, et al.

    Objective. This study is aimed at teasing out the correlation of plasma D‐dimer (D‐D) levels to age, metastasis, TNM stage (tumor‐node‐metastasis classification), and treatment in non‐small‐cell lung cancer (NSCLC) patients of different ages, to facilitate early diagnosis of hypercoagulable state, choose appropriate treatment, and use appropriate anticoagulants. Hence, thrombosis and complications caused by excessive anticoagulants can be prevented; thrombus or disseminated intravascular coagulation (DIC) and other complications in elderly patients with NSCLC can be reduced or avoided. By monitoring the level of plasma D‐D in patients with NSCLC, recurrence and metastasis can be predicted in the early stage and the TNM stage can be evaluated. Methods. A total of 670 patients with NSCLC were selected in Shanxi Bethune Hospital from March 2014 to October 2020 as the experimental group, and 950 healthy people were selected from the physical examination center of the same hospital as the control group. The data of patients with NSCLC diagnosed for the first time without any treatment were collected and grouped based on metastasis, TNM stage, treatment, and pathological type, and the correlation with plasma D‐D level was analyzed. Plasma D‐D levels were measured by immunoturbidimetry on an ACL TOP 700 Automatic Coagulation Analyzer. The patients were further divided into two groups according to different treatment methods, and the differences in plasma D‐D levels between patients receiving chemotherapy and those receiving targeted therapy in different treatment cycles were analyzed. The correlation between D‐D levels and age in healthy controls was analyzed. The difference in D‐D levels between NSCLC patients and healthy controls of the same age was analyzed. Results. All data of both the experimental group and the control group were normally distributed. The average age of the experimental group was 61.31 ± 6.23 (range: 36‐92) years. The average age of the control group was 61.14 ± 11.12 (range: 35‐85) years. There was no significant difference in gender between the experimental group and the control group (p > 0.05). The plasma D‐D level of NSCLC patients was significantly higher than that of the healthy controls (p < 0.05). No significant difference in plasma D‐D level was found between NSCLC patients of different genders, and the finding was similar between healthy controls of different genders (p > 0.05). Significant difference in the D‐D level was found between the groups of 30‐59 years and 60‐69 years (p < 0.05), between groups of 60‐69 years and 70‐79 years (p < 0.05), and between 70‐79 years and ≥80 years (p < 0.05). The plasma D‐D level of patients ≤ 79 years old increased with age, but it decreased in those over 80 years old. According to Pearson correlation analysis, there was a positive correlation between the D‐D level and the age of NSCLC patients under 79 years old (p < 0.05). The differences in D‐D levels between the four age groups were statistically significant (p < 0.05), showing an upward trend of the D‐D level in healthy controls with the increase of age. There were statistically significant differences in D‐D levels between NSCLC patients and healthy controls of the matching age group (p < 0.05), suggesting that NSCLC patients had significantly higher D‐D levels than healthy people of the same age group. The differences in D‐D levels between NSCLC patients without metastasis, NSCLC patients with metastasis, and healthy people were statistically significant (p < 0.05). The patients with metastasis had the highest D‐D level, and healthy people had the lowest D‐D level. The difference in plasma D‐D levels between patients of different TNM stages was statistically significant (p < 0.05). Patients with an advanced TNM stage tended to have higher D‐D levels. The TNM stage and D‐D level of NSCLC patients changed significantly before and after treatment. An earlier stage was related to a more obvious change in D‐D levels after treatment with a statistically significant difference (p < 0.05). A more advanced stage was associated with a smaller change in the D‐D level after treatment, with no statistically significant difference (p > 0.05). The plasma D‐D levels before and after four cycles of chemotherapy or targeted therapy were higher than those of the healthy control group, and the differences were statistically significant (p < 0.05). The D‐D level of patients after chemotherapy was significantly lower than that before chemotherapy (p < 0.05), but there was no significant difference before and after targeted therapy (p > 0.05). The D‐D level after the first cycle of chemotherapy was higher than that before chemotherapy. The level of D‐D after the third and fourth cycles was significantly lower than that before chemotherapy (p < 0.05). No significant difference was found between the D‐D level before treatment and that after four cycles of chemotherapy (p > 0.05). Conclusion. It is suggested that coagulation test indexes should be included to evaluate the treatment regimen for NSCLC patients. Most patients with NSCLC are in a hypercoagulable state, which is related to age, tumor invasion and metastasis, recurrence, and treatment. Regular monitoring of plasma D‐D levels can facilitate early diagnosis of a hypercoagulable state and timely and appropriate use of anticoagulants, to avoid or reduce complications such as venous thromboembolism in NSCLC patients and to prevent the risk of bleeding caused by excessive anticoagulants. Clinicians can choose the treatment with less harm and maximum benefit for NSCLC patients based on the plasma D‐D level. When in a hypercoagulable state, the body’s blood viscosity increases, making it more conducive to the growth and infiltration of tumor cells. Our study shows that the recurrence and metastasis of NSCLC are related to coagulation indexes, which provides a theoretical basis for the early diagnosis and treatment of recurrent and metastatic NSCLC.


  • Open Access

    Femoral artery plaque characteristics, lower extremity collaterals, and mobility loss in peripheral artery disease

    by Mary M McDermott, Timothy Carroll, James Carr, Chun Yuan, Luigi Ferrucci, Jack M Guralnik, Melina Kibbe, Michael H Criqui, Lu Tian, Tamar Polonsky, et al.

    Little is known about the prognostic significance of specific characteristics of magnetic resonance imaging (MRI) measured plaque in the superficial femoral artery (SFA). Associations of MRI-measured plaque quantity, lumen area, and plaque composition in the SFA with subsequent mobility loss were studied in people with lower extremity peripheral artery disease (PAD). Participants with an ankle–brachial index (ABI) < 1.00 were identified from Chicago medical centers and underwent direct visualization of atherosclerotic plaque in the SFA using MRI. Participants were followed annually for up to 4 years. Mobility loss was defined as becoming unable to walk up and down a flight of stairs or walk one-quarter of a mile without assistance among participants without mobility impairment at baseline. Analyses adjusted for age, sex, race, comorbidities, ABI, physical activity, and other confounders. Of 308 PAD participants without baseline mobility impairment, 100 (32.5%) developed mobility loss during follow-up. Compared to the lowest mean plaque area tertile at baseline, participants in the highest (worst) plaque area tertile had a higher rate of mobility loss (hazard ratio (HR) = 2.08, 95% confidence interval (CI) = 1.14–3.79, p = 0.018). Compared to the highest mean lumen area tertile, the smallest (worst) mean lumen area tertile was associated with greater mobility loss (HR = 2.18, 95% CI = 1.20–3.96, p = 0.011). Neither lipid rich necrotic core nor calcium in the SFA were associated with mobility loss. In conclusion, greater plaque quantity and smaller lumen area in the proximal SFA, but not lipid rich necrotic core or calcium, were associated with higher mobility loss in people with PAD.


  • Abstract 13797: Effects of Resveratrol Supplementation on Walking Performance in Peripheral Artery Disease: A Randomized Clinical Trial

    by Mary McDermott, Christiaan Leeuwenburgh, Luigi Ferrucci, Jack M Guralnik, Robert Sufit, Lu Tian, Lihui Zhao, James Stein, Ying Gao, Stephen Anton, et al.

  • Open Access

    Community walking speed, sedentary or lying down time, and mortality in peripheral artery disease

    by Mary M McDermott, Jack M Guralnik, Luigi Ferrucci, Lu Tian, Melina R Kibbe, Philip Greenland, David Green, Kiang Liu, Lihui Zhao, John T Wilkins, et al.

    We studied whether slower community walking speed and whether greater time spent lying down or sleeping were associated with higher mortality in people with lower extremity peripheral artery disease (PAD). Participants with an ankle–brachial index (ABI) < 0.90 were identified from Chicago medical centers. At baseline, participants reported their usual walking speed outside their home and the number of hours they spent lying down or sleeping per day. Cause of death was adjudicated using death certificates and medical record review. Analyses were adjusted for age, sex, race, comorbidities, ABI, and other confounders. Of 1314 PAD participants, 189 (14.4%) died, including 63 cardiovascular disease (CVD) deaths. Mean follow-up was 34.9 months ± 18.1. Relative to average or normal pace (2–3 miles/hour), slower walking speed was associated with greater CVD mortality: no walking at all: hazard ratio (HR) = 4.17, 95% confidence interval (CI) = 1.46–11.89; casual strolling (0–2 miles/hour): HR = 2.24, 95% CI = 1.16–4.32; brisk or striding (>3 miles/hour): HR = 0.55, 95% CI = 0.07–4.30. These associations were not significant after additional adjustment for the six-minute walk. Relative to sleeping or lying down for 8–9 hours, fewer or greater hours sleeping or lying down were associated with higher CVD mortality: 4–7 hours: HR = 2.08, 95% CI = 1.06–4.05; 10–11 hours: HR = 4.07, 95% CI = 1.86–8.89; ⩾12 hours: HR = 3.75, 95% CI = 1.47–9.62. These associations were maintained after adjustment for the six-minute walk. In conclusion, slower walking speed outside the home and less than 8 hours or more than 9 hours lying down per day are potentially modifiable behaviors associated with increased CVD mortality in patients with PAD.


  • Elevated β1,4-galactosyltransferase-I induced by the intraspinal injection of lipopolysaccharide

    by Aiguo Shen, Jianping Chen, Ji Qian, Jianchun Zhu, Ling Hu, Meijuan Yan, Dan Zhou, Ying Gao, Junling Yang, Fei Ding, et al.

    β1,4-Galactosyltransferase-I (β1,4-GalT-I) is one of the best studied glycosyltransferases. Previous studies demonstrated that β1,4-GalT-I was a major galactosyltransferase responsible for selectin-ligand biosynthesis and that inflammatory responses of β1,4-GalT-I deficient mice were impaired. In this study, we investigate the expression of β1,4-GalT-I in lipopolysaccharide (LPS)-induced neuroinflammatory processes. The results of this study demonstrated that β1,4-GalT-I was strongly induced by intraspinal administration of LPS. More than 90% galactose-containing glycans and β1,4-GalT-I were expressed in immune cells. The ELISA assay shows focal injection LPS also induces TNF-α alteration. Double staining indicated β1,4-GalT-I overlapped with TNF-α. Moreover, RT-PCR for β1,4-GalT-I mRNA showed that β1,4-GalT-I mRNA in microglia in vitro was affected in a dose- and time dependent manner in response to LPS or TNF-α stimulation. All these results indicated that the increase of β1,4-GalT-I might attribute to the effect of TNF-α excreting during inflammation. E-selectin, which ligand was modified by β1,4-GalT-I, was correlated with galactose-containing glycans following injecting LPS into spinal cord. We therefore suggest that β1,4-GalT-I may play an important role in regulating immune cell migration into the inflammatory site.